Filing Flows › Ironwood Pharmaceuticals (IRWD) › Q3 2025
Ironwood Pharmaceuticals (IRWD) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 10, 2025
Ironwood Pharmaceuticals (IRWD) reported revenue of $122M for the third quarter 2025 (Q3 2025), +33% from a year earlier and +43% from the quarter before. Operating margin was 61.8%, net earnings $40.1M (32.8% of revenue).
Ironwood Pharmaceuticals, Q3 2025: revenue $122M (+33% year over year), operating margin 61.8%, net earnings $40.1M, operating cash flow $47.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $122M | +43% | +33% |
| Operating profit | $75.5M | +67% | +194% |
| Net earnings | $40.1M | +70% | +999% |
| Operating cash flow | $47.6M | — | +381% |
| Free cash flow | $47.6M | — | +382% |
What changed
Revenue was $122.1M in Q3 2025, up 33% year over year and up 43% from the previous quarter.
Operating profit was $75.5M, a 61.8% margin (up 33.9 points year over year). Of the extra revenue versus a year earlier, 164% reached operating profit, above the 28% margin then. Total costs fell 29% while revenue rose 33%. Net earnings were $40.1M, up 999% year over year. The effective tax rate was 41.1%.
Operating cash flow was $47.6M (up 381% year over year), 119% of net earnings. Non-cash charges added back $475K of depreciation and $3.6M of share-based compensation. Working capital and other items added $3.4M. Capital expenditures of $2K left free cash flow of $47.6M.
Questions
What was Ironwood Pharmaceuticals' revenue in the third quarter 2025?
Ironwood Pharmaceuticals (IRWD) reported revenue of $122M for the third quarter 2025 (Q3 2025), +33% from a year earlier and +43% from the quarter before.
Was Ironwood Pharmaceuticals profitable in the third quarter 2025?
Operating profit was $75.5M (61.8% of revenue) and net earnings $40.1M.